Shares of Edap Tms SA (NASDAQ:EDAP) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $6.50 for the company, according to Zacks. Zacks has also given Edap Tms an industry rank of 64 out of 257 based on the ratings given to its competitors.
EDAP has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating on shares of Edap Tms in a research report on Tuesday, September 4th. Zacks Investment Research lowered Edap Tms from a “hold” rating to a “sell” rating in a research report on Friday, September 7th. Finally, TheStreet lowered Edap Tms from a “c” rating to a “d+” rating in a research report on Friday, September 28th.
Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Wednesday, November 14th. The medical equipment provider reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $9.47 million during the quarter, compared to analyst estimates of $10.34 million. Edap Tms had a negative return on equity of 4.08% and a negative net margin of 3.93%. On average, equities research analysts expect that Edap Tms will post -0.05 EPS for the current year.
A hedge fund recently bought a new stake in Edap Tms stock. Fosun International Ltd acquired a new position in Edap Tms SA (NASDAQ:EDAP) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 170,627 shares of the medical equipment provider’s stock, valued at approximately $526,000. Fosun International Ltd owned 0.59% of Edap Tms as of its most recent filing with the Securities & Exchange Commission. 8.89% of the stock is currently owned by institutional investors and hedge funds.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Recommended Story: What is cost of equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.